9989 (9989) Fair Value & Analysis

Healthcare · Market cap HK$6.1B

9 9989 9989 · HK

PriceHK$4.14

Fair ValueHK$6.24

Upside+50.7%

Quality58/100

Watch 9989 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$4.54 – HK$7.56

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price −1.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.83 – HK$6.61 · fair‑value band HK$4.54 – HK$7.56 · the HK$4.14 price screens below the HK$6.24 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9989 (9989) currently trades at HK$4.14, while our model-based Fair Value estimate is HK$6.24 — implying the stock looks roughly 50.7% undervalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 9989 generated revenue of HK$5.4B at a net margin of 7.0%. Revenue declined 4.5% year over year. It earns a return on equity of 3.0%. Net debt stands at HK$763M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$5.4B

Revenue growth (YoY) -4.5%

Net margin 7.0%

Return on equity 3.0%

Free cash flow HK$1.6B FY2025

P/E ratio 13.8

More key figures

Operating margin 14.4%

EPS (TTM) HK$0.2743

Dividend yield 3.6%

EPS growth (YoY) +19.8%

Net debt HK$763M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9989 reported revenue of HK$5.5B in FY2025 versus HK$6.4B in FY2021, a compound −3.7%/yr. Reported net income was HK$349M in FY2025, compounding +9.8%/yr from FY2021.

Revenue −3.7%/yr

FY21 HK$6.4B

FY22 HK$7.2B

FY23 HK$5.4B

FY24 HK$5.3B

FY25 HK$5.5B

Net income +9.8%/yr

FY21 HK$241M

FY22 HK$727M

FY23 −HK$783M

FY24 HK$647M

FY25 HK$349M

Is 9989 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9989 (9989) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$6.24 versus a price of HK$4.14 — about +51% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 9989?

Our model-based fair value for 9989 is HK$6.24 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$4.14.

What is the quality score of 9989?

9989 has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9989 (9989)?

9989 reported trailing-twelve-month revenue of about HK$5.4B (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 9989?

The net profit margin of 9989 is about 7.0%, meaning it keeps roughly 7.0% of revenue as net income. Based on the latest reported figures.

Does 9989 pay a dividend?

9989 currently shows a dividend yield of about 3.60% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.